CD38 and Miyoshi myopathy: Selinexor plus dexamethasone (Sel‐dex) was approved by the U.S. Food and Drug Administration (FDA) in July, 2019 for treating patients with MM refractory to at least two PIs, at least two IMiDs, and an anti‐CD38 mAb (penta‐refractory), based on data from the Phase IIb STORM study [10].